STOCK TITAN
  1. Home
  2. Sec-filings
  3. GPCR
  4. [Form 4] Structure Therapeutics Inc. American Insider Trading Activity

[Form 4] Structure Therapeutics Inc. American Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Insider Yoon Jun
Role CHIEF FINANCIAL OFFICER
Type Security Shares Price Value
Grant/Award Ordinary Shares 39,606 $0.00 --
Tax Withholding Ordinary Shares 7,089 $6.8366 $48K
Grant/Award American Depositary Shares 831 $0.00 --
Tax Withholding Ordinary Shares 5,940 $7.9166 $47K
holding Ordinary Shares -- -- --
Holdings After Transaction: Ordinary Shares — 1,326,965 shares (Direct); American Depositary Shares — 2,946 shares (Direct); Ordinary Shares — 1,554,586 shares (Indirect, See footnote)
Footnotes (1)
  1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date. By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019. Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Yoon Jun
(Last) (First) (Middle)
C/O STRUCTURE THERAPEUTICS INC.
601 GATEWAY BLVD., SUITE 900
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
03/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 03/01/2025 F 5,940(2) D $7.9166 1,287,359 D
Ordinary Shares(1) 07/01/2025 A(3) 39,606 A $0 1,326,965 D
Ordinary Shares(1) 07/01/2025 F 7,089(2) D $6.8366 1,319,876 D
Ordinary Shares(1) 1,554,586 I See footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
American Depositary Shares (5) 05/21/2025 A V 831 (5) (5) Ordinary Shares(1) 2,963 $0 2,946 D
Explanation of Responses:
1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
3. On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.
4. By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019.
5. Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.
/s/ Jun Yoon 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR